Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam B Shapiro

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Virology Journal|November 20, 2014
Quantitative investigation of the affinity of human respiratory syncytial virus phosphoprotein C-terminus binding to nucleocapsid proteinAdam B Shapiro, Ning Gao, Nichole O'Connell, et al.
Antimicrobial Agents and Chemotherapy|October 16, 2023
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of <i>Acinetobacter baumannii</i>Samir H Moussa, Adam B Shapiro, Sarah M McLeod, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2012
Inhibitors of acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Part 1: Hit to lead evaluation of a novel arylsulfonamide seriesOluyinka M Green, Andrew R McKenzie, Adam B Shapiro, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2014
NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacyThomas J Dougherty, Asha Nayar, Joseph V Newman, et al.
ACS Infectious Diseases|September 15, 2016
Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation MappingDavid C McKinney, Charles J Eyermann, Rong-Fang Gu, et al.
European Journal of Medicinal Chemistry|February 26, 2025
Small molecule inhibitors of mannan-binding lectin-associated serine Proteases-2 and-3Mina C Nakhla, Janelle Comita, Adam B Shapiro, et al.
The Biochemical Journal|June 23, 2012
An aminoquinazoline inhibitor of the essential bacterial cell wall synthetic enzyme GlmU has a unique non-protein-kinase-like binding modeNicholas A Larsen, Tory J Nash, Marshall Morningstar, et al.
Journal of Bacteriology|July 31, 2012
Novel rapidly diversifiable antimicrobial RNA polymerase switch region inhibitors with confirmed mode of action in Haemophilus influenzaeEd T Buurman, Melinda A Foulk, Ning Gao, et al.
The Journal of Biological Chemistry|October 11, 2011
In vitro validation of acetyltransferase activity of GlmU as an antibacterial target in Haemophilus influenzaeEd T Buurman, Beth Andrews, Ning Gao, et al.
Bioconjugate Chemistry|October 17, 2015
Nuclear Targeting with an Auger Electron Emitter Potentiates the Action of a Widely Used Antineoplastic DrugSebastian Imstepf, Vanessa Pierroz, Paula Raposinho, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Virology Journal|November 20, 2014
Quantitative investigation of the affinity of human respiratory syncytial virus phosphoprotein C-terminus binding to nucleocapsid proteinAdam B Shapiro, Ning Gao, Nichole O'Connell, et al.
Antimicrobial Agents and Chemotherapy|October 16, 2023
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of <i>Acinetobacter baumannii</i>Samir H Moussa, Adam B Shapiro, Sarah M McLeod, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2012
Inhibitors of acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Part 1: Hit to lead evaluation of a novel arylsulfonamide seriesOluyinka M Green, Andrew R McKenzie, Adam B Shapiro, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2014
NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacyThomas J Dougherty, Asha Nayar, Joseph V Newman, et al.
ACS Infectious Diseases|September 15, 2016
Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation MappingDavid C McKinney, Charles J Eyermann, Rong-Fang Gu, et al.
European Journal of Medicinal Chemistry|February 26, 2025
Small molecule inhibitors of mannan-binding lectin-associated serine Proteases-2 and-3Mina C Nakhla, Janelle Comita, Adam B Shapiro, et al.
The Biochemical Journal|June 23, 2012
An aminoquinazoline inhibitor of the essential bacterial cell wall synthetic enzyme GlmU has a unique non-protein-kinase-like binding modeNicholas A Larsen, Tory J Nash, Marshall Morningstar, et al.
Journal of Bacteriology|July 31, 2012
Novel rapidly diversifiable antimicrobial RNA polymerase switch region inhibitors with confirmed mode of action in Haemophilus influenzaeEd T Buurman, Melinda A Foulk, Ning Gao, et al.
The Journal of Biological Chemistry|October 11, 2011
In vitro validation of acetyltransferase activity of GlmU as an antibacterial target in Haemophilus influenzaeEd T Buurman, Beth Andrews, Ning Gao, et al.
Bioconjugate Chemistry|October 17, 2015
Nuclear Targeting with an Auger Electron Emitter Potentiates the Action of a Widely Used Antineoplastic DrugSebastian Imstepf, Vanessa Pierroz, Paula Raposinho, et al.
Pageof 6